Investment
Features
FeesSafety
Academy
More
Pluang+

Ericsson beats Q3 earnings estimates on strong mobile network demand despite margin concerns for 2027

Company Fundamentals
15 Oct 2026
Danny Green
View Source
Bullish
Ericsson beats Q3 earnings estimates on strong mobile network demand despite margin concerns for 2027

Ericsson reported better-than-expected Q3 earnings with EPS of $0.18 and revenue of $5.91 billion, driven by strong demand in its mobile network segment. The Networks division showed 9% organic growth and a gross margin above guidance, but overall operating profit and net income declined due to a one-off gain in the previous year. Analysts are cautious about Ericsson's margin sustainability in 2027, citing rising component costs and competitive pricing pressures. Following the report, Ericsson's shares rose 9% to $10.43, reflecting investor optimism despite margin concerns.

Ericsson's Q3 earnings beat expectations, reported as of Oct 16, 2026 00:41 WIB. For readers following the Technology sector, here is Pluang's market snapshot as of that time: out of 150 priced US tech stocks, 91 rose and 58 fell. Notable movers include Hewlett Packard Enterprise Co (HPE) at USD 59.43 with a 1-day change of -5.92% and Pluang order activity showing 77% Sell / 23% Buy, Infosys Limited (INFY) at USD 12.15 up 5.88% with 94% Sell / 6% Buy, and Keysight Technologies Inc (KEYS) at USD 336.66 down 5.85% with 99% Sell / 1% Buy. The most notable figure is INFY's 5.88% price increase.

More News

Scotiabank raises Targa Resources price target to $319, citing strong momentum and a $1.25 dividend.

Scotiabank raises Targa Resources price target to $319, citing strong momentum and a $1.25 dividend.

Scotiabank increased its price target for Targa Resources to $319 from $314, indicating a potential 12.7% upside from the current share price of around $283. Targa Resources, a key player in the midstream energy sector, is recognized as a top momentu...

Analyst Insights
Bullish
1 hour ago
Over 200 companies advance next-gen obesity drugs with new therapies and clinical trials surging globally

Over 200 companies advance next-gen obesity drugs with new therapies and clinical trials surging globally

The obesity treatment landscape is rapidly evolving with over 200 companies developing more than 200 pipeline drugs, including late-stage and early-stage clinical trials. Major pharmaceutical firms like Novo Nordisk and Eli Lilly are leading with inn...

Market News
Bullish
1 hour ago
Alice, Inflection AI, and AI21 show NVIDIA Nemotron models can be trained for advanced AI safety and security.

Alice, Inflection AI, and AI21 show NVIDIA Nemotron models can be trained for advanced AI safety and security.

Alice collaborated with Inflection AI and AI21 to demonstrate that NVIDIA Nemotron open models can be post-trained using real-world adversarial data to enhance AI safety and security without losing capability. Inflection AI improved conversational AI...

Market News
Bullish
1 hour ago
Stifel reaffirms Buy on Accenture with $242 target amid strong AI-driven growth and 13.4% stock rise.

Stifel reaffirms Buy on Accenture with $242 target amid strong AI-driven growth and 13.4% stock rise.

Stifel Nicolaus has reiterated a Buy rating for Accenture with a price target of $242, reflecting confidence in the company's strong recent stock performance and growth prospects. Accenture's shares rose 13.4% in the month leading up to October 15, 2...

Analyst Insights
Bullish
2 hours ago
CCC Intelligent Solutions downgraded as $6.1B acquisition offer at $7.75/share announced

CCC Intelligent Solutions downgraded as $6.1B acquisition offer at $7.75/share announced

Investment firm William Blair downgraded CCC Intelligent Solutions to Market Perform amid news of a $6.1 billion acquisition by a consortium led by GTCR and Elliott Investment Management. Shareholders will receive $7.75 per share, a premium over rece...

Market News
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App